Shanghai Kehua Bio-Engineering (SHE:002022) obtained medical device registration from the Shanghai regulator for its high-density lipoprotein 3 cholesterol assay kit.
The kit is intended for in vitro quantitative determination of HDL3-C concentration in human serum and plasma samples, according to a Tuesday filing with the Shenzhen bourse.
The registration is valid until May 6, 2031.
Shares of the in vitro diagnostics company closed 3% lower Tuesday.
Guangzhou Metro Design & Research Institute (SHE:003013) signed eight contracts worth a preliminary 252.2 million yuan with controlling shareholder Guangzhou Metro for the Xilang and Yuzhu depot renovation projects.The contracts constitute related party transactions, according to a Tuesday filing with the Shenzhen bourse.Shares of the engineering services provider closed 1% lower Tuesday.
Daikin Industries' (TYO:6367) profit attributable to owners of the parent increased to 275.23 billion yen for fiscal year 2025 from 264.76 billion yen a year earlier.The air conditioner manufacturer's earnings per share increased to 939.14 yen from 903.65 yen a year ago, according to a Tokyo bourse filing on Tuesday.Net sales jumped 5.5% to 5.015 trillion yen for the year ended March 31 from 4.752 trillion yen in the prior year.Daikin also declared a year-end dividend of 175 yen per share, payable from June 29, compared with 145 yen a year ago.For the fiscal year 2026, the company expects attributable profit of 278 billion yen, EPS of 949.32 yen, and net sales of 5.150 trillion yen. It also plans to pay per-share interim and year-end dividends of 180 yen each.